Clinical data | |
---|---|
Trade names | Hydra, Hyzyd, Isovit, others |
Other names | isonicotinic acid hydrazide, isonicotinyl hydrazine, INH, INAH, INHA |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682401 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth, intramuscular, intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | Very low (0–10%) |
Metabolism | liver; CYP450: 2C19, 3A4 inhibitor |
Elimination half-life | 0.5–1.6h (fast acetylators), 2-5h (slow acetylators) |
Excretion | urine (primarily), feces |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
NIAID ChemDB | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.195 |
Chemical and physical data | |
Formula | C6H7N3O |
Molar mass | 137.142 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Isoniazid, also known as isonicotinic acid hydrazide (INH), is an antibiotic used for the treatment of tuberculosis.[4] For active tuberculosis, it is often used together with rifampicin, pyrazinamide, and either streptomycin or ethambutol.[5] For latent tuberculosis, it is often used alone.[4] It may also be used for atypical types of mycobacteria, such as M. avium, M. kansasii, and M. xenopi.[4] It is usually taken by mouth, but may be used by injection into muscle.[4]